Danaher plans to launch an AI-powered autonomous research lab in 2027

Danaher, a company in the life sciences sector, has announced that it expects to launch its first autonomous AI-based research laboratory in early 2027, with the stated goal of accelerating drug discovery and development. According to the Reuters report on which this information is based, the lab will operate at full scale from that year.

The plan is to combine AI, robotics and technologies from several of the companies operating under the Danaher umbrella within a single connected workflow. The specific aim of that workflow is the development of custom antibodies and other molecular tools, that is, molecules designed for biomedical science and, potentially, for therapies.

In terms of performance, the company claims the system will make it possible to discover molecules up to eight times faster, and to multiply tenfold the number of target-binding molecules that can be generated each year. Both figures come directly from Danaher's announcement, not from independent verification.

The operation described is a closed design-build-test-learn loop: the AI helps propose new molecules capable of binding specifically to a given biological target —including antibodies— after which the system physically builds and tests each one, and every experimental result is fed back into the model to improve the design of the next generation of candidates. This is the usual pattern of so-called autonomous labs or "self-driving labs," where robotic automation is combined with models that learn from each experimental iteration, reducing the need for a scientist to manually design every test.

JC Gutierrez-Ramos, Danaher's chief science officer, has explained that this automation "frees scientists to focus on the complex scientific challenges where human judgment matters most," positioning the project as a complement to scientific work rather than a complete replacement for researchers.

According to Danaher itself, this laboratory is a concrete example of a broader program the company is developing internally, aimed at creating what it calls a "fleet of smart instruments," that is, interconnected, AI-enhanced lab instrumentation that would go beyond this specific use case in antibody discovery.

It is worth qualifying the real scope of the news: this is a corporate announcement about future plans, with a date for operation at scale still set in the first months of 2027, and the improvement figures (8x and 10x) are the company's own projections, not yet tested against public results from real production. The source does not detail aspects such as the financial investment allocated to the project, the rollout timelines across Danaher's various subsidiaries, or concrete examples of molecules or drugs already developed with this system.

In any case, the announcement fits into a broader trend within the biopharmaceutical and life sciences industry, where various companies are betting on combining laboratory robotics with AI models to compress molecular discovery timelines, traditionally one of the costliest and slowest bottlenecks in the development of new treatments.